Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

In a UK-wide immuno-oncology program, John Baker says IMU's pre-treatment immune profile separates patients likely to respond to anti-PD-L1 or checkpoint inhibitor combinations. It also flags before the first dose who may suffer severe immune-mediated adverse events, so clinicians can monitor and manage those patients more actively. Response rates are only 30-40%.

Related Insights

Early Phase 3 trials like JAVELIN adding immunotherapy to chemoradiation failed to improve outcomes. However, subgroup analyses consistently showed a potential benefit in PD-L1 high-expressing patients, a crucial lesson that informed the design of subsequent, more successful studies.

Despite immunotherapy's success in other lung cancers, it is completely ineffective for patients with ROS1 fusions. A large global data series showed a 0% response rate. These genetically-driven cancers are "cold tumors," making upfront genomic testing critical to avoid futile and toxic treatment with checkpoint inhibitors.

A common clinical observation is that patients who develop significant immune-related toxicities, like colitis or pneumonitis, are frequently the same ones who experience the most profound and durable responses to checkpoint inhibitor therapy.

ITP caused by immune checkpoint inhibitors (ICIs) is rare (0.25% incidence) but generally has a good prognosis. Most patients respond to standard first-line ITP therapies, and approximately 70% of those re-challenged with the ICI can continue treatment without a recurrence of ITP.

Post-approval, real-world data for Tarlatumab shows higher-than-expected rates of serious toxicities like ICANS. This has created a clinical need for a 'risk calculator' that uses patient variables like tumor burden and liver metastases to identify who is at high risk, allowing for proactive management like elective hospitalization.

The adoption of nivolumab+AVD in community oncology is streamlined because practitioners are already experienced with managing immune-related adverse events from using checkpoint inhibitors in various solid tumors. This existing familiarity flattens the learning curve for this new lymphoma regimen.

The discontinuation rate for pembrolizumab due to side effects was lower in the LITESPARK 022 trial compared to the earlier Keynote 564 trial (20%). This trend suggests that as clinicians gain more experience with immune checkpoint inhibitors, they are becoming more adept at managing immune-related adverse events, allowing more patients to complete their therapy.

The belief that immune-related adverse events (irAEs) predict better response to immunotherapy is likely confounded by survival bias. Patients must remain on treatment long enough to both respond and develop an irAE. This extended duration creates a correlation that may not be causal.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

Data shows that patients who permanently stopped ipilimumab due to immune-related side effects still had exceptionally good outcomes. This gives clinicians confidence to manage toxicity by discontinuing the CTLA-4 inhibitor portion of the regimen while continuing nivolumab, without fearing a loss of efficacy.